Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Coluracetam
Also known as: MKC-231, BCI-540
Coluracetam is a fat-soluble racetam originally developed by Mitsubishi Tanabe Pharma for Alzheimer's disease. It is unique among racetams for its potent enhancement of high-affinity choline uptake (HACU), and users frequently report vivid color vision enhancement as a distinctive subjective effect.
Risk Level
Low RiskDifficulty
Advanced| CAS Number | 135463-81-9 |
| Molecular Formula | C19H23N3O3 |
| Class | Other |
| Category | Nootropics |
Mechanism of Action
Coluracetam works primarily through potent and selective enhancement of high-affinity choline uptake (HACU) at cholinergic synapses, increasing the rate of acetylcholine synthesis. Unlike other HACU enhancers, its effects persist long after the drug has been cleared, suggesting lasting modification of the choline uptake system. It also showed activity in BrainCells Inc. Phase IIa trials for major depressive disorder with comorbid anxiety.
Dosing Research
Typical dose: 20-80 mg/day sublingually, divided into 2-3 doses. Most common: 20-35 mg sublingually twice daily. Sublingual preferred due to poor oral bioavailability. Half-life approximately 2-3 hours but effects on HACU are longer-lasting. Very limited human dosing data — start at the low end.
Side Effects & Risks
Very limited safety data. Reported: headache, fatigue, nausea. The visual enhancement effect (HD vision) reported by users is not well characterized in literature. No known serious adverse effects in short-term use. Long-term safety completely unknown. Expensive and difficult to source reliably.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.